公开(公告)号：US20240245694A1

公开(公告)日：2024-07-25

申请号：US18483651

申请日：2023-10-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Markus FUREGATI ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Ziyue HONG ,  Fabio LIMA ,  Fatma LIMAM ,  Henrik MOEBITZ ,  Sandro NOCITO ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG ,  Frédéric ZECRI ,  Huangchao YU ,  Yong ZHANG ,  Xinkan YANG ,  Sisi ZHANG ,  Wei LI

IPC: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20240197715A1

公开(公告)日：2024-06-20

申请号：US18510836

申请日：2023-11-16

Applicant: NOVARTIS AG

Inventor： Rita ANDRAOS-REY ,  Sandra BLUM-KALLERT ,  Marta CORTES-CROS ,  Ruben DE KANTER ,  Stephane FERRETTI ,  Isabel Cristina Colaco Farias JACO ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Laurent LABORDE ,  Henrik MOEBITZ ,  Michele MOSCHETTA ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG

IPC: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I):




wherein R1, R2, R3, R4, R5, R28, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein.

公开(公告)号：US20240360118A1

公开(公告)日：2024-10-31

申请号：US18506164

申请日：2023-11-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07B2200/13

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20230046859A1

公开(公告)日：2023-02-16

申请号：US17824407

申请日：2022-05-25

Applicant: NOVARTIS AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.